Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics.
about
Probing GABA receptor function in schizophrenia with iomazenilPositive allosteric modulation of metabotropic glutamate 5 (mGlu5) receptors reverses N-Methyl-D-aspartate antagonist-induced alteration of neuronal firing in prefrontal cortexClozapine, but not haloperidol, enhances glial D-serine and L-glutamate release in rat frontal cortex and primary cultured astrocytesPAOPA, a potent analogue of Pro-Leu-glycinamide and allosteric modulator of the dopamine D2 receptor, prevents NMDA receptor antagonist (MK-801)-induced deficits in social interaction in the rat: implications for the treatment of negative symptoms iTo use or not to use: an update on licit and illicit ketamine useAnimal models of schizophrenia: a critical reviewCelecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On TrialsLegal highs: staying on top of the flood of novel psychoactive substancesContribution of NMDA receptors to dorsolateral prefrontal cortical networks in primatesPositive allosteric modulators of metabotropic glutamate 2 receptors in schizophrenia treatmentThe cytokine model of schizophrenia: emerging therapeutic strategiesNeuroimaging findings in treatment-resistant schizophrenia: A systematic review: Lack of neuroimaging correlates of treatment-resistant schizophreniaRestoration of Sp4 in Forebrain GABAergic Neurons Rescues Hypersensitivity to Ketamine in Sp4 Hypomorphic Mice.Acute NMDA receptor antagonism disrupts synchronization of action potential firing in rat prefrontal cortexHistamine H3 receptors and its antagonism as a novel mechanism for antipsychotic effect: a current preclinical & clinical perspectiveDrug models of schizophreniaJumping to conclusions in schizophreniaMeta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophreniaEffects of phencyclidine (PCP) and MK 801 on the EEGq in the prefrontal cortex of conscious rats; antagonism by clozapine, and antagonists of AMPA-, alpha(1)- and 5-HT(2A)-receptorsAmphetamine-induced Fos is reduced in limbic cortical regions but not in the caudate or accumbens in a genetic model of NMDA receptor hypofunctionAllosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's diseaseDysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoringRemoving obstacles in neuroscience drug discovery: the future path for animal models.Neuroactive Steroids are Altered in Schizophrenia and Bipolar Disorder: Relevance to Pathophysiology and TherapeuticsNicotinic ligands as multifunctional agents for the treatment of neuropsychiatric disordersThe auditory steady-state response (ASSR): a translational biomarker for schizophrenia.Altered glutamate protein co-expression network topology linked to spine loss in the auditory cortex of schizophrenia.Effects of the nicotinic α7 receptor partial agonist GTS-21 on NMDA-glutamatergic receptor related deficits in sensorimotor gating and recognition memory in ratsInhibition of protein translation by the DISC1-Boymaw fusion gene from a Scottish family with major psychiatric disorders.Impaired limbic cortico-striatal structure and sustained visual attention in a rodent model of schizophrenia.Disruption of dopamine neuron activity pattern regulation through selective expression of a human KCNN3 mutation.Electrophysiological and behavioral responses to ketamine in mice with reduced Akt1 expression.How Nox2-containing NADPH oxidase affects cortical circuits in the NMDA receptor antagonist model of schizophrenia.Prolonged Ketamine Effects in Sp4 Hypomorphic Mice: Mimicking Phenotypes of Schizophrenia.Mouse pharmacological models of cognitive disruption relevant to schizophrenia.Genetic models of sensorimotor gating: relevance to neuropsychiatric disorders.Assessment of glutamate transporter GLAST (EAAT1)-deficient mice for phenotypes relevant to the negative and executive/cognitive symptoms of schizophrenia.Acute administration of typical and atypical antipsychotics reduces EEG γ power, but only the preclinical compound LY379268 reduces the ketamine-induced rise in γ power.Role of the NMDA-receptor in Prepulse Inhibition in the Rat.Are cross-species measures of sensorimotor gating useful for the discovery of procognitive cotreatments for schizophrenia?
P2860
Q24601700-247BBA50-6602-4D20-949E-462BE16F97FDQ24602550-2DF33725-5AFA-479B-819B-1495EF480947Q24606088-39F71B58-4265-4E7B-B428-87AC08856D36Q24621061-FC74BF55-75F7-4E69-B713-34CD5E0D4261Q24634006-1648DDB1-1B15-478D-8313-83AC3A5C4588Q24674909-0F9D8C5C-76EE-421A-9C6D-5E9E2A90744DQ26741541-D412A4E0-93BE-47F8-815E-9AC7F386D997Q26799231-972AB252-4D7E-4530-907D-B5D16C2C96E3Q26820417-7B2EF881-F4AD-4310-9F30-96975FE4C280Q26852047-F7349BD0-666C-46EF-A8E6-1E6CED64FECCQ26865996-B0362D70-7A04-4EF9-8B57-8EA9395B71D7Q27026382-12E21CB8-ED66-4C7D-99C2-4ADEAC971420Q27300750-35ECDC07-ABB8-463C-AF78-14528B0A2C69Q27332387-171966FE-FE26-4FCD-87F6-E029D3635366Q28073102-CDCD6DBD-63C6-4684-B10D-7DC322AA08E1Q28084198-57305F32-993D-40E4-AAD2-7B329A72A558Q28087488-D7B66432-3632-42C4-860D-26D808B4DF4BQ28248687-FAF47607-BB79-4225-A614-860F4BA271F8Q28344844-73FC3133-940D-476A-B14D-63EF140153D8Q28590145-80E22792-D87A-4490-8AA2-3BFD07751E91Q28660933-39FD3B3E-BE88-4AB0-B3DB-143D686905CCQ28754716-3193692A-8BF0-493B-BDB8-274F052C6932Q28755229-56F28037-46CA-4464-A6BA-46A8024F4A21Q29011855-6F281A5D-9213-48D8-BF0F-CB19145BD61BQ30372351-ECD3EECC-DF12-4932-BF6A-B13320EDBB26Q30378324-AEE0301C-F510-49BA-905E-28035C24A64BQ30382204-C0D0DA07-8AF0-459F-BF56-EAA2D065AB15Q30391389-112F7374-ACB4-4F2A-8DD2-56B10608D582Q30399814-DFE5B599-B793-4D8E-938E-5C8D76D6727EQ30403790-09E72BD5-771C-4399-9D49-F18939297A27Q30425716-4828FB03-FA38-4EE5-88A7-753143BDF549Q30437684-66222A6F-A614-4C3D-806D-3A3C28FA3385Q30439924-B7839188-D751-4E4F-BE15-1E09250A1115Q30452766-028D6BD1-E95F-45D5-99F3-E7439952645DQ30457807-37926655-9491-4B09-80D9-B8D08D33B5ACQ30459497-7AF3A3B8-D80C-4C57-9EAC-05B5CCA4176CQ30465586-63F48F62-76EF-41D1-932B-6D043825CB61Q30466734-FA76ABF7-FAC8-4985-A5F1-90008DDDADB4Q30472936-D06DE9A9-58A9-4235-BC25-17C4244AEE13Q30473418-1BE08E7E-221E-4F36-A1A7-1B1E2AF9186B
P2860
Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh-hant
name
Ketamine-induced exacerbation ...... uroleptic-free schizophrenics.
@en
Ketamine-induced exacerbation ...... uroleptic-free schizophrenics.
@nl
type
label
Ketamine-induced exacerbation ...... uroleptic-free schizophrenics.
@en
Ketamine-induced exacerbation ...... uroleptic-free schizophrenics.
@nl
prefLabel
Ketamine-induced exacerbation ...... uroleptic-free schizophrenics.
@en
Ketamine-induced exacerbation ...... uroleptic-free schizophrenics.
@nl
P2093
P1476
Ketamine-induced exacerbation ...... uroleptic-free schizophrenics.
@en
P2093
P304
P356
10.1016/S0893-133X(97)00036-5
P407
P50
P577
1997-09-01T00:00:00Z
P6179
1024306761